Traders should view this as a validation of D-PLEX₁₀₀’s pharmacokinetic profile, strengthening its differentiation and regulatory pathway. With FDA Breakthrough status and strong Phase 3 data already demonstrated, this reinforces near-term approval potential and partnership prospects, especially in a high-unmet-need area like surgical infections.
Price Chart
Executive Summary
PolyPid announced new pharmacokinetic data from its Phase 3 SHIELD II trial showing sustained, controlled release of D-PLEX₁₀₀ with detectable doxycycline levels at the surgical site for up to 32 days and minimal systemic exposure. The data will be presented at ESCMID Global 2026, reinforcing the drug’s mechanism of action for preventing surgical site infections.
Key Facts
- D-PLEX₁₀₀ showed detectable doxycycline concentrations for up to 763 hours (32 days) post-surgery with no burst release.
- Plasma concentrations remained below 100 ng/mL, indicating negligible systemic exposure compared to oral doxycycline (Cmax ~1,600–2,600 ng/mL).
- Data supports D-PLEX₁₀₀’s mechanism: localized, prolonged antibiotic delivery over 30 days at surgical site.
- D-PLEX₁₀₀ previously demonstrated 60% relative risk reduction in SSIs (p=0.0013) in the SHIELD II trial.
- D-PLEX₁₀₀ has FDA Breakthrough Therapy designation for SSI prevention in elective colorectal surgery.
Financial Impact
Positive catalyst for regulatory momentum and commercial potential; no direct financials reported.
Risk Factors
- Forward-looking statements are subject to regulatory delays or rejection.
- Commercial adoption may depend on physician behavior and reimbursement dynamics.
- Company has limited market cap ($82M), making it highly sensitive to sentiment and liquidity risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272567 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $4.90 | awaiting T+60 | — | $5.67 (+15.71%) |
Oct 1, 2026 26d ago | 6-K | $5.37 | awaiting T+60 | — | $5.67 (+5.59%) |
Oct 1, 2026 26d ago | Press Release | $5.37 | awaiting T+60 | — | $5.67 (+5.59%) |
Oct 1, 2026 26d ago | 6-K | $5.37 | awaiting T+60 | — | $5.67 (+5.59%) |
Oct 1, 2026 26d ago | Press Release | $5.37 | awaiting T+60 | — | $5.67 (+5.59%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.67 (+18.62%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.67 (+17.15%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.67 (+17.15%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.67 (+38.97%) |
Jul 21, 2026 14w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.67 (+51.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers